0 16 n 5 for u2018 mptp u2019 and u2018 saline u2019 controls respectively and a value similar to that of the u2018 healthy u2019 control of 1 02 u00b1 0 23 n 5 for treatment with u2018 u03b1syn grp94 u2019 differing from that obtained with the treatment with u2018 u03b1syn u2019 or u2018 grp94 u2019 alone 1 98 u00b1 0 39 n 5 2 01 u00b1 0 55 n 5 fig5 these results demonstrate that immunization with a combination of u03b1syn both in the non aggregated and oligomeric forms and the chaperone grp94 produces different effects on the immune response of the immunized mice and that the adoptive transfer of splenocytes originating from said immunization is capable of preventing or counteracting the development of symptoms related to parkinson 39 s disease in the recipient mice vaccination of a transgenic mice model of als sod1 g93a with an hsp70 and sod1 combination to evaluate their als therapeutic prophylactic capacity a preliminary experiment was conducted to evaluate the therapeutic potential of immunization with a combination of sod1 and the chaperone hsp70 to that end a transgenic mice model of als tg sod1 g93a jackson laboratories inc u s a was used with mice 9 weeks of age 3 mice per.